The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Moderna is likely to bring its cancer vaccine to market first, focusing on lung and skin cancers. 9 Out of the Last 10 Summers this "Power Pattern" Delivered Winners - Get The Details Now.

The proportions of beneficiaries receiving Pfizer-BioNTech and Moderna booster doses between August 1, 2021, and April 30, 2022, were similar; we identified 10,501,525 Pfizer-BioNTech booster ...

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest, most ...